Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol
Sarah Nikiforow(Otsuka (Japan)), Susan E. Prockop(Memorial Sloan Kettering Cancer Center), Faith Galderisi(Atara Biotherapeutics (United States)), Wen‐Kai Weng(Stanford University), Donald E. Tsai(University of Pennsylvania), Laurence Gamelin(Atara Biotherapeutics (United States)), Eneida R. Nemecek(Oregon Health & Science University), David M. Loeb(Albert Einstein College of Medicine), Koen van Besien(University Hospitals of Cleveland), Kris M. Mahadeo(Duke University), Justin T. Wahlstrom(University of California, San Francisco), Rajani Dinavahi(Atara Biotherapeutics (United States)), Jennifer Whangbo(Boston Children's Hospital), Aditi Mehta(Atara Biotherapeutics (United States)), Ran Reshef(Abramson Cancer Center), Sunita D. Nasta(University of Pennsylvania), Yan Sun(Shanghai Jiao Tong University), Rolla Abu‐Arja(Nationwide Children's Hospital), Weizhi Zhao(Atara Biotherapeutics (United States)), Nancy Bunin(University of Iowa)
Cited by 23
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
|New England Journal of Medicine|2020|1.4k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k